Skip to content

China Dialysis Calcification Study

Prevalence and predictive value of vascular calcification for mortality in patients with chronic kidney disease on dialysis in China

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-14004447
Enrollment
Unknown
Registered
2014-03-28
Start date
2014-04-15
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Sponsors

Nanjing General Hospital of Nanjing Military Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or Female patients 18 years old and elder; 2. Patients with ESRD receiving stable HD or PD at least 6 months; 3. Patient or legally accepted representitive willing to sign Consent Form.

Exclusion criteria

Exclusion criteria: 1. Patients' life expectancy <6 months; 2. Patients with acute kidney injury, active inflammatory diseases, parathyroidectomy or evident malignancies; 3. Patients with conditions making arterial calcification measurements technically impossible or unreliable, such as cardiac arrhythmias, amputations or severe peripheral vascular lesions; 4. Concomitant diseases that affect calcium status and soft tissue calcifications (sarcoidosis, multiple myeloma, HIV, amyloidosis); 5. Pregnant or lactating women or women planning to become pregnant in the 6 months following entry into the study.

Design outcomes

Primary

MeasureTime frame
In Chinese CKD patients undergoing HD or PD, to determine prevalence of CAC, AAC and cardiac valve calcification at baseline;

Secondary

MeasureTime frame
Evaluate hazard ratio of all-cause/CVD mortality and non-fatal CV events to the risk factor of baseline VC including CAC, AAC and cardiac valve calcification at 24 months follow up;Hazard ratio of all-cause/CVD mortality and non-fatal CV events to the disease management including serum level of calcium, phosphorus and iPTH, and Different kind of phosphate binders including calcium-based binders, lanthanum-based binders, aluminum-based binders and sevelamer, Other calcium supplements, Vitamin D;Evaluate the impact of disease management (including serum level of calcium, phosphorus and iPTH, and medications), ABI, and LVMI/LVH on the occurrence and severities (scores) of CAC, AAC and cardiac valve calcification at baseline;Determine the percentage of patients achieving serum phosphorus, calcium and iPTH according to K/DOQI and KDIGO guidelines, respectively;Assess the sensitivity and specificity of CCI for predicting CAC;

Countries

China

Contacts

Public ContactFan YANG
Fan4.yang@sanofi.com+86 10 65634967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026